The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Fixed-dose vs weight-based plerixafor in patients with SCD receiving BEAM-101 in the BEACON trial
Haydar Frangoul, MD, MS, Sarah Cannon Research Institute at TriStar Centennial Children’s Hospital, Nashville, TN, discusses an analysis from the ongoing BEACON study (NCT05456880), which evaluated the use of fixed-dose versus weight-based plerixafor dosing in patients with sickle cell disease (SCD) receiving autologous CD34+ base-edited hematopoietic stem cells (BEAM-101). Dr Frangoul highlights that patients receiving fixed-dose plerixafor required fewer days and fewer cycles of apheresis due to more efficient mobilization and greater stem cell yield. He also reports on the early engraftment and efficacy data from the study. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
